WEKO3
アイテム
Evaluation of Patient-specific Quality Assurance for Spot-Scanning Carbon Ion Radiotherapy
https://repo.qst.go.jp/records/81596
https://repo.qst.go.jp/records/81596059fee55-3e4a-4c8a-b4ed-db63d62abfb0
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-01-08 | |||||
| タイトル | ||||||
| タイトル | Evaluation of Patient-specific Quality Assurance for Spot-Scanning Carbon Ion Radiotherapy | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
猪俣, 麻美
× 猪俣, 麻美× 鈴木, 優維× 勝間田, 匡× 中島, 猛雄× 古市, 渉× 山岡, 恵士× 菅, 満喜人× 山本, 淳史× 水野, 秀之× 河野, 良介× Asami, Inomata× Yui, Suzuki× Masashi, Katsumata× Nakajima, Takeo× Wataru, Furuichi× Keisi, Yamaoka× Makito, Suga× Atsushi, Yamamoto× Hideyuki, Mizuno× Ryosuke, Kohno |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | [Purpose] In the QST hospital, carbon ion radiotherapy (CIRT) using spot-scanning was started in 2011. In order to check each individual CIRT treatment plan and its treatment delivery, the scanning system and its treatment planning system require dosimetric patient-specific Quality Assurance (PQA) before CIRT. We report results of PQA in half year of 2017. [Methods] For the PQA, all the planned beams are recalculated on a water phantom with treatment planning software. The recalculated dose distributions are compared with the measured distributions using a 2D ionization chamber array at three depth, including 95% area of prescription dose. These are evaluated using 3%/3 mm gamma criteria with a pass threshold of 90%. We analyzed PQA results for about 1500 shots from September 2017 to March 2018, evaluated the pass rate for 10 disease sites with various target volume, energy and measurement depth. [Results] The pass rate for prostate, head and neck, and bone and soft tissue were 95.9%, 99.3%, and 91.5%, respectively. 95.9% of lung plans with low energy beam passed. Overall, 95% of the measured beams for all shots passed the gamma criteria, and were consistent with the plan. Although the rest of 5% failed the criteria, there were no dependence of measurements depth and disease sites in these failures. [Conclusion] The results of the PQA in the second half of FY2017 was analyzed. The overall quality assurance measurement passing rate was 95% for the gamma index criteria of 3%/3 mm. It was obvious that there was no disease sites or target dependency in these pass rates. Therefore, we could ensure the safety of the CIRT treatment plans. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第119回日本医学物理学会学術大会 | |||||
| 発表年月日 | ||||||
| 日付 | 2020-05-15 | |||||
| 日付タイプ | Issued | |||||
